By DAMIAN WONJO
Every clinician keeps a private list of the patients they don’t see. Not the ones who cancel, the ones who never book. The shift worker who reschedules the same appointment three times and then quietly gives up. The parent who can’t justify half a day off and a waiting-room afternoon for a routine refill. The patient whose condition carries enough stigma that the friction of a face-to-face visit becomes, in itself, a reason to do nothing. These people don’t show up in no-show statistics. They show up later, as complications, as emergencies, as avoidable deterioration.
This is the access gap, and from where I sit as a physician in Europe, it has less to do with the raw supply of doctors than with the cost of reaching one, measured not only in money but in time, distance, and effort. When that cost climbs higher than a patient’s tolerance, care simply doesn’t happen. Online prescription services and remote consultation won’t fix every part of this problem. But they target precisely the variable that most reforms ignore, which is friction.
The patients who fall through
It is tempting to frame telemedicine as a convenience for the already-healthy and already-connected. In practice, the people who benefit most are often those with the least slack in their lives. A patient stabilised on the same antihypertensive for three years does not need a fresh diagnostic odyssey to continue it, they need a prescription before they run out. A working adult who recognises a recurring, familiar problem does not always need a physical examination to be helped safely. Forcing every such encounter through the narrow door of an in-person appointment does not raise the standard of care, it raises the rate at which people abandon it.
Continuity is where this matters most. Chronic conditions are managed in refills, and a missed refill is not a clerical event but a gap in treatment with real physiological consequences. Lowering the barrier to that refill is not a luxury. It is, quietly, one of the highest-yield interventions available.
What changed in Europe
The pandemic did not invent telemedicine, but it normalised it, and it accelerated the infrastructure underneath it. Poland is a useful case study. Electronic prescriptions became the national standard in 2020, and today essentially every prescription is issued digitally, retrievable by the patient through a government health account and dispensable at any pharmacy with a code. The clinical encounter and the prescription were decoupled from a single physical location without being decoupled from a licensed prescriber.
That distinction is the whole argument. A responsible online prescription service is not a vending machine. It is a licensed physician, working within the same legal and ethical framework as any clinic, using a different channel to reach the patient. The technology is mundane. The consequence, that a patient who would otherwise have gone without is now seen, is not.
The honest limits
I want to be precise about where this model should not go, because credibility depends on it. Remote prescribing is appropriate for continuation of stable therapy, for clearly defined and low-risk presentations, and for situations where a careful history is genuinely sufficient. It is not appropriate as a substitute for examination when red-flag symptoms are present, for escalating or undifferentiated complaints, for most controlled substances, or wherever the absence of a physical exam meaningfully raises risk. A good service builds those boundaries into its triage and refers patients onward when the safe answer is that this needs to be seen in person.
Telemedicine that ignores those limits does not close the access gap, it relocates risk. The clinicians and platforms doing this well are the ones most willing to turn patients away from the online channel when that is the right call. Convenience is the feature. Clinical judgment is still the product.
What the conversation often misses
Debates about online prescribing tend to collapse into a binary, either it is dangerous shortcutting or it is frictionless progress. Neither framing is useful. The more honest question is narrower. For which patients, and which problems, does removing the friction of an in-person visit improve outcomes without degrading safety? For a large and underserved middle, meaning stable chronic patients, predictable refills, and conditions people are reluctant to present in person, the answer is increasingly clear. For acute, complex, or high-risk care, it remains no.
Health systems on both sides of the Atlantic spend enormous energy expanding capacity and almost none reducing the friction that wastes it. A patient who never books is invisible to a system optimised around the patients who do. Online prescription services, used within proper limits, make some of those invisible patients visible again. That is not a revolution. It is something more durable, a quiet correction to a gap we had simply stopped noticing.
Dr Damian Wojno is a physician who collaborates with the Polish telemedicine service eRecepta Online24.
